摘要
目的观察文拉法辛与帕罗西汀治疗抑郁症的临床疗效及安全性。方法入选对象为2012年6月～2015年6月确诊的首发抑郁症的住院患者60例,全部患者采用随机数字表法随机分为对照组（帕罗西汀组）和治疗组（文拉法辛组）,各30例,疗程8周,治疗后比较两组的临床疗效及HAMD评分、不良反应情况。结果治疗组患者的临床总有效率虽高于对照组,两组间比较差异无统计学意义（90.00%vs 80.00%,P〉0.05）。治疗组治疗1周、2周末的HAMD评分分别较对照组显著降低,但治疗4、8周末后,两组HAMD评分分别组间比较,差异无统计学意义（P〉0.05）。治疗组的不良反应发生率明显低于对照组,差异有统计学意义（P〈0.05）。结论文拉法辛与帕罗西汀治疗抑郁症均具有较好的临床疗效,但文拉法辛起效更快,且安全性更好,值得广泛推广和应用。
Objective To observe the clinical efficacy and safety of venlafaxine and paroxetine in treatment of depression. Methods 60 patients with the first episode depression were selected from June 2012 to June 2015. All patients were randomly divided into control group（paroxetine group） and treatment group（venlafaxine group）, 30 cases in each group, 8 weeks after treatment, the clinical curative effect, HAMD, and adverse reactions were compared. Results The total effective rate of the treatment group was higher than that of the control group, there was no significant difference between the two groups（90.0% vs 80.0%, P〉0.05）. The treatment group for 1 week, 2 weeks of HAMD score were significantly lower than the control group, but after treatment 4, 8 weeks, the HAMD score between the two groups were compared, the difference was not statistically significant（P〉0.05）. The adverse reaction rate in the treatment group was lower than that in the control group, the difference was statistically significant（P〈0.05）. Conclusion Venlafaxine and paroxetine in the treatment of depression have good clinical efficacy, but venlafaxine is effective, and the safety is better, it is worth widely spreading and application.
出处
《中国现代医生》
2016年第3期100-102,共3页
China Modern Doctor
